These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 36346503

  • 21. 99mTc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen.
    Xu X, Zhang J, Hu S, He S, Bao X, Ma G, Luo J, Cheng J, Zhang Y.
    Nucl Med Biol; 2017 May; 48():69-75. PubMed ID: 28273495
    [Abstract] [Full Text] [Related]

  • 22. Intraindividual Comparison of 99mTc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand 99mTc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer.
    Rathke H, Afshar-Oromieh A, Giesel FL, Kremer C, Flechsig P, Haufe S, Mier W, Holland-Letz T, De Bucourt M, Armor T, Babich JW, Haberkorn U, Kratochwil C.
    J Nucl Med; 2018 Sep; 59(9):1373-1379. PubMed ID: 29371410
    [Abstract] [Full Text] [Related]

  • 23. Comparison of hybrid 68Ga-PSMA-PET/CT and 99mTc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: Additional value of morphologic information from low dose CT.
    Janssen JC, Meißner S, Woythal N, Prasad V, Brenner W, Diederichs G, Hamm B, Makowski MR.
    Eur Radiol; 2018 Feb; 28(2):610-619. PubMed ID: 28779400
    [Abstract] [Full Text] [Related]

  • 24. Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy.
    Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, Joyal J, Kopka K, Debus J, Babich JW, Haberkorn U.
    Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1280-92. PubMed ID: 24577951
    [Abstract] [Full Text] [Related]

  • 25. Diagnostic efficacy of [99mTc]Tc-PSMA SPECT/CT for prostate cancer: a meta-analysis.
    Wang Q, Ketteler S, Bagheri S, Ebrahimifard A, Luster M, Librizzi D, Yousefi BH.
    BMC Cancer; 2024 Aug 08; 24(1):982. PubMed ID: 39118101
    [Abstract] [Full Text] [Related]

  • 26. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer.
    Vallabhajosula S, Nikolopoulou A, Babich JW, Osborne JR, Tagawa ST, Lipai I, Solnes L, Maresca KP, Armor T, Joyal JL, Crummet R, Stubbs JB, Goldsmith SJ.
    J Nucl Med; 2014 Nov 08; 55(11):1791-8. PubMed ID: 25342385
    [Abstract] [Full Text] [Related]

  • 27. Patient-specific radiation dosimetry of 99mTc-HYNIC-Tyr3-octreotide in neuroendocrine tumors.
    Grimes J, Celler A, Birkenfeld B, Shcherbinin S, Listewnik MH, Piwowarska-Bilska H, Mikolajczak R, Zorga P.
    J Nucl Med; 2011 Sep 08; 52(9):1474-81. PubMed ID: 21795364
    [Abstract] [Full Text] [Related]

  • 28. Diagnostic performance of 99mTc-HYNIC-PSMA SPECT/CT for biochemically recurrent prostate cancer after radical prostatectomy.
    Li B, Duan L, Shi J, Han Y, Wei W, Cheng X, Cao Y, Kader A, Ding D, Wu X, Gao Y.
    Front Oncol; 2022 Sep 08; 12():1072437. PubMed ID: 36568205
    [Abstract] [Full Text] [Related]

  • 29. Head to head comparison performance of 99mTc-EDDA/HYNIC-iPSMA SPECT/CT and 68Ga-PSMA-11 PET/CT a prospective study in biochemical recurrence prostate cancer patients.
    García-Pérez FO, Davanzo J, López-Buenrostro S, Santos-Cuevas C, Ferro-Flores G, Jímenez-Ríos MA, Scavuzzo A, Santana-Ríos Z, Medina-Ornelas S.
    Am J Nucl Med Mol Imaging; 2018 Sep 08; 8(5):332-340. PubMed ID: 30510850
    [Abstract] [Full Text] [Related]

  • 30. 177Lu-DOTA-HYNIC-Lys(Nal)-Urea-Glu: Biokinetics, Dosimetry, and Evaluation in Patients with Advanced Prostate Cancer.
    Santos-Cuevas C, Ferro-Flores G, García-Pérez FO, Jiménez-Mancilla N, Ramírez-Nava G, Ocampo-García B, Luna-Gutiérrez M, Azorín-Vega E, Davanzo J, Soldevilla-Gallardo I.
    Contrast Media Mol Imaging; 2018 Sep 08; 2018():5247153. PubMed ID: 30534027
    [Abstract] [Full Text] [Related]

  • 31. Biodistribution and radiation dosimetry of [18F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET/CT imaging of prostate cancer.
    Hohberg M, Kobe C, Krapf P, Täger P, Hammes J, Dietlein F, Zlatopolskiy BD, Endepols H, Wild M, Neubauer S, Heidenreich A, Neumaier B, Drzezga A, Dietlein M.
    EJNMMI Res; 2019 Jul 25; 9(1):66. PubMed ID: 31346821
    [Abstract] [Full Text] [Related]

  • 32. The Value of 99mTc-PSMA SPECT/CT-Guided Surgery for Identifying and Locating Lymph Node Metastasis in Prostate Cancer Patients.
    Su HC, Zhu Y, Hu SL, Liu C, Lin GW, Dai B, Zhang YJ, Ye DW.
    Ann Surg Oncol; 2019 Feb 25; 26(2):653-659. PubMed ID: 30324468
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [Initial experiences with 99mTc-PSMA-SPECT/CT in patients with prostate cancer].
    Farkas I, Besenyi Z, Maráz A, Bajory Z, Palkó A, Sipka G, Pávics L.
    Orv Hetil; 2018 Sep 25; 159(35):1433-1440. PubMed ID: 30146905
    [Abstract] [Full Text] [Related]

  • 35. Design, synthesis, radiolabeling and biological evaluation of new urea-based peptides targeting prostate specific membrane antigen.
    Mosayebnia M, Hajimahdi Z, Beiki D, Rezaeianpour M, Hajiramezanali M, Geramifar P, Sabzevari O, Amini M, Hatamabadi D, Shahhosseini S.
    Bioorg Chem; 2020 Jun 25; 99():103743. PubMed ID: 32217372
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Optimizing PSMA scintigraphy for resource limited settings - a retrospective comparative study.
    Kolade OU, Brink A, Ayeni AO, More S, Holness J.
    Cancer Imaging; 2024 Apr 01; 24(1):46. PubMed ID: 38556864
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes.
    Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, Kong G, Kumar AR, Thang SP, Eu P, Scalzo M, Murphy D, Williams S, Hicks RJ, Hofman MS.
    J Nucl Med; 2019 Apr 01; 60(4):517-523. PubMed ID: 30291192
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.